91 related articles for article (PubMed ID: 23791157)
21. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant breast radiotherapy using a simultaneous integrated boost: clinical and dosimetric perspectives.
Alford SL; Prassas GN; Vogelesang CR; Leggett HJ; Hamilton CS
J Med Imaging Radiat Oncol; 2013 Apr; 57(2):222-9. PubMed ID: 23551785
[TBL] [Abstract][Full Text] [Related]
23. Effect of patient variation on standard- and hypo-fractionated radiotherapy of prostate cancer.
Xiong W; Li J; Ma CM
Phys Med Biol; 2005 Apr; 50(7):1483-92. PubMed ID: 15798338
[TBL] [Abstract][Full Text] [Related]
24. A randomised controlled trial to evaluate both the role and the optimal fractionation of radiotherapy in the conservative management of early breast cancer.
Spooner D; Stocken DD; Jordan S; Bathers S; Dunn JA; Jevons C; Dodson L; Morrison JM; Oates GD; Grieve RJ;
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):697-706. PubMed ID: 23036277
[TBL] [Abstract][Full Text] [Related]
25. Acute toxicity and 2-year adverse effects of 30 Gy in five fractions over 15 days to whole breast after local excision of early breast cancer.
Martin S; Mannino M; Rostom A; Tait D; Donovan E; Eagle S; Haviland J; Yarnold J
Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):502-5. PubMed ID: 18556186
[TBL] [Abstract][Full Text] [Related]
26. Cancer trends in Sweden until 2010.
Acta Oncol; 1996; 35 Suppl 6():37-45. PubMed ID: 9154084
[TBL] [Abstract][Full Text] [Related]
27. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
28. Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy x 1) versus multiple fractions (3 Gy x 10) in the treatment of painful bone metastases.
Kaasa S; Brenne E; Lund JA; Fayers P; Falkmer U; Holmberg M; Lagerlund M; Bruland O
Radiother Oncol; 2006 Jun; 79(3):278-84. PubMed ID: 16793154
[TBL] [Abstract][Full Text] [Related]
29. Variation, precision and validity of 1-year survival estimates for lung, breast, colon and prostate cancer in South East England primary care trusts.
Lake J; Mak V; Møller H; Davies EA
Public Health; 2012 Jan; 126(1):57-63. PubMed ID: 22153886
[TBL] [Abstract][Full Text] [Related]
30. The impact of hypofractionated whole breast radiotherapy on local relapse in patients with Grade 3 early breast cancer: a population-based cohort study.
Herbert C; Nichol A; Olivotto I; Weir L; Woods R; Speers C; Truong P; Tyldesley S
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2086-92. PubMed ID: 21477936
[TBL] [Abstract][Full Text] [Related]
31. Mathematical modelling of radiotherapy strategies for early breast cancer.
Enderling H; Anderson AR; Chaplain MA; Munro AJ; Vaidya JS
J Theor Biol; 2006 Jul; 241(1):158-71. PubMed ID: 16386275
[TBL] [Abstract][Full Text] [Related]
32. Hypofractionated radiotherapy in prostate cancer.
Vavassis P; Nguyen DH; Bahary JP; Yassa M
Expert Rev Anticancer Ther; 2012 Jul; 12(7):965-72. PubMed ID: 22845411
[TBL] [Abstract][Full Text] [Related]
33. Carbon ion radiotherapy in advanced hypofractionated regimens for prostate cancer: from 20 to 16 fractions.
Okada T; Tsuji H; Kamada T; Akakura K; Suzuki H; Shimazaki J; Tsujii H;
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):968-72. PubMed ID: 22898380
[TBL] [Abstract][Full Text] [Related]
34. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of hypofractionated image-guided radiotherapy for localized prostate cancer: outcomes of 55 Gy in 16 fractions at 3.4 Gy per fraction.
Wu JS; Brasher PM; El-Gayed A; Pervez N; Tai PT; Robinson J; Skarsgard D; Joseph K; Sia MA; Pearcey RG
Radiother Oncol; 2012 May; 103(2):210-6. PubMed ID: 22280805
[TBL] [Abstract][Full Text] [Related]
36. Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison.
Leborgne F; Fowler J
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1441-6. PubMed ID: 19395194
[TBL] [Abstract][Full Text] [Related]
37. The influence of age and comorbidity on receiving radiotherapy as part of primary treatment for cancer in South Netherlands, 1995 to 2002.
Vulto AJ; Lemmens VE; Louwman MW; Janssen-Heijnen ML; Poortmans PH; Lybeert ML; Coebergh JW
Cancer; 2006 Jun; 106(12):2734-42. PubMed ID: 16703598
[TBL] [Abstract][Full Text] [Related]
38. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.
Patel N; Faria S; Cury F; David M; Duclos M; Shenouda G; Ruo R; Souhami L
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):534-9. PubMed ID: 23597418
[TBL] [Abstract][Full Text] [Related]
39. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?
Sanguineti G; Cavey ML; Endres EJ; Franzone P; Barra S; Parker BC; Marcenaro M; Colman M; Agostinelli S; Foppiano F; Vitale V
Strahlenther Onkol; 2006 Sep; 182(9):543-9. PubMed ID: 16944377
[TBL] [Abstract][Full Text] [Related]
40. Radiotherapy services. Ministry of Health, New Zealand.
N Z Health Hospital; 1996; 48(1):23-4. PubMed ID: 10157236
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
